Cybin Corp.

The QualityStocks Daily Newsletter would like to spotlight Cybin Corp..

Cybin Corp. is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Recent News

• Cybin Corp. is “One to Watch”
• Cybin Corp. and IntelGenx Corp. to Collaborate in Development of Fast-Acting Psilocybin Film
• Cybin Corp. Announces Reverse Take-Over and Up-To $21M Concurrent Private Placement

DarioHealth Corp. (NASDAQ: DRIO)

The QualityStocks Daily Newsletter would like to spotlight DarioHealth Corp. (DRIO).

New York and Israel-based DarioHealth Corp. (NASDAQ: DRIO) leads global digital therapeutics (DTx) with its popular, smartphone-centered personalized chronic illness management software-as-a-service (SaaS). The company’s strategic advantages include:

• AI-powered digital solutions that drive durable behavior change in chronic disease patients, and
• Personalized user experience at scale to make behavior change the path of least resistance.

Approximately $3 trillion in annual U.S. costs associated with chronic illnesses like diabetes, hypertension and obesity are largely preventable with behavioral therapies. Formerly limited to periodic office visits, these therapies can now scale to millions with tech-enabled, continual and remote health monitoring, as well as AI-driven digital and live coaching. This is all possible while still maintaining the personalization required for success in reducing illness and its related effects and costs.

Roughly 51,000 active, paying users manage their health with Dario’s platform that combines smartphone-connected vitals measurement, remote patient monitoring (RPM), lifestyle management tools, and AI-driven and human coaching to deliver improved clinical outcomes.

Among the most downloaded medical apps, the Dario platform is rated at 4.9 stars on the Apple App Store and features 11,000 reviews, along with a Net Promoter Score (a measurement of consumers’ willingness to recommend the product to others) that’s the highest in its field.

Company Strategy

Clinical studies demonstrate Dario’s direct improvement on users’ health measures like H1AC scores (diabetes) and blood pressure (hypertension).

Patient engagement in therapies leads to health success. Dario’s platform centers on continual maximization of patient engagement through personalization, including ‘nudges’ and live, AI-generated responses to health measures provided by Dario’s smartphone-connected medical devices.

Proprietary data analysis provides valuable insights that not only improve health care providers’ medical capabilities but, through artificial intelligence, encourage patients to take evidence-based and highly personalized preventative measures that reduce risk, emergency room visits and preventable hospitalization.

Dario is now deploying its successful B2C platform in B2B2C, targeting employers and health plans with competitive advantages in cost, software and hardware.

The company estimates an annual addressable U.S. market of $72 billion, only 1% of which has been penetrated with digital therapeutics.

The strategic transition to B2B2C (from exclusively B2B) is intended to accelerate revenue growth by reducing Dario’s cost per acquisition per user and expanding margins.

Dario’s commitment to aggressive growth is also shown by its appointment of a new president, chief medical officer and head of sales for North America, all from a highflyer behavioral health company.

Key growth drivers planned include expansion of the company’s paying B2C subscriber base; lateral expansion into other chronic conditions that overlap with its core diabetes populations, such as hypertension, obesity and depression; and increased B2B2C penetration.

Financial Highlights

The company plans to leverage a massive opportunity for growth, with a global addressable market for digital therapeutics of roughly $108 billion. In the U.S. alone, that number is estimated at $72 billion, and only about 1% of that market has been penetrated.

Dario’s strategic transition to an SaaS membership business model increased gross profit by 87% in Q1 2020, as compared to the prior year. Membership revenue increased from 27.1% to 46.7% in the same period. The company is seeing improved operating efficiencies as it shifts focus to the B2B2C business model, and it expects average revenue per user per month (ARPU), which was $6 and $25 in 2019 and 2020, respectively, to reach $70.

Value to Consumers and Businesses

Dario continually evaluates and optimizes the value and return its platform delivers to consumers and businesses.

Consumers seeking to understand how their everyday behavior impacts their personal health and chronic conditions benefit from actionable feedback on how to improve health and better collaborate with health care providers.

Businesses looking to increase employee satisfaction, loyalty and productivity with fewer health-related absences take advantage of Dario’s services for employers.

Health care providers improve patient compliance using the platform’s interactive services that allow for greater monitoring, which improve engagement with patients at the right times and with the right treatments.

Health plans can leverage DarioHealth’s solutions to improve patient outcomes and lower costs.

Recent Studies

The company recently presented the results of two new studies at the American Diabetes Association’s 80th Scientific Sessions, which showed sustained improvements in blood glucose levels and blood pressure among users of its digital therapeutic platform for chronic diseases. The results of these two studies demonstrate that the use of Dario’s therapeutic platform promotes behavioral modification, enhanced individual engagement and improved clinical outcomes.

Remote Patient Monitoring (RPM) Agreements

The Centers for Medicare & Medicaid Services recently approved RPM codes for Medicare patients, which enables physicians to bill for between-visit patient care.

This simplifies implementation of the company’s open and scalable AI-driven platform and further supports transition to the company’s high-margin, recurring SaaS model targeting B2B2C revenue channels.

Emergency COVID-19 FDA Guidelines Allow Self-Test Blood Glucose Meters

In an effort to preserve personal protective equipment (PPE) and reduce contact between health care providers and patients in hospital settings due to COVID-19, the U.S. Food and Drug Administration (FDA) has recognized that home-use blood glucose meters, including Dario’s smartphone-connected metering device, may be used by patients with diabetes who are hospitalized due to COVID-19 to check their own blood glucose levels and provide the readings to the health care personnel caring for them.

As a result, hospitals can now allow patients to self-test using their Dario blood glucose testing strips and smartphone-connected devices, or hospitals can issue patients Dario devices upon admission for COVID-19-related conditions.

Irregularities in blood glucose levels are suspected as a factor in the increased severity of potentially deadly COVID-19 complications. As such, a high priority is being placed on stabilization of patients’ blood glucose levels.

Awards and Recognition

DarioHealth’s Blood Glucose Monitoring System was voted as the ‘Best Glucometer for Data Management’ by Top Ten Reviews. Jeph Preece, senior editor at Top Ten Reviews, said, “The Dario app is the best data management system that I’ve seen. Compared to apps by popular brands, Dario’s system looks and feels like it’s years ahead of the curve.”

‘The Global Digital Health 100’, an annual award sponsored by the reputable Journal of Health, recognized DarioHealth as a leader among health technology companies demonstrating the greatest potential to change the way that health care is delivered.

DarioHealth Corp. (DRIO), closed Tuesday's trading session at $6.88, up 6.6667%, on 53,569 volume with 335 trades. The average volume for the last 3 months is 71,193 and the stock's 52-week low/high is $3.01999998/$13.1260004.

Recent News

• DarioHealth Corp. (NASDAQ: DRIO) is "One to Watch"
• DarioHealth Corp. (NASDAQ: DRIO) Announces Board Appointment of Veteran Health Plan Executive
• DarioHealth Corp. (NASDAQ: DRIO) Announces KOL Call on Digital Therapeutics for Management of Diabetes and Other Chronic Conditions

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

Energy Fuels (NYSE American: UUUU) (TSX: EFR), the largest uranium producer in the United States and the leading conventional producer of vanadium, appears well positioned to capitalize on the recent attention that nuclear power has attracted, both in the United States and abroad. A recent push for nuclear power by the International Energy Association (“IEA”) and OECD Nuclear Energy Agency, two major international organizations, recognizes immense benefits of this energy source for both economic recovery and energy supply resilience in the post-COVID19 world.

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR), based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

• White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
• Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
• Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon-free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

• Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
• Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
• Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

• La Sal Complex (Utah)
• Whirlwind Mine (Colorado/Utah)
• Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

 

Energy Fuels Inc. (UUUU), closed Tuesday's trading session at $1.59, up 1.2739%, on 948,983 volume with 2,974 trades. The average volume for the last 3 months is 1,720,533 and the stock's 52-week low/high is $0.779999971/$3.25.

Recent News

• Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) to Capitalize as Nuclear Takes Center Stage
• Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Supporting Clean Energy with Alternate-Feed Material Recycling Program
• Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Finalizes Agreements with Rare Earth Element Industry Experts to Advance Commercial, Technical Strategies

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced it has completed its acquisition of Quantitative Medicine LLC (“QM”), a biomedical analytics and computational biology company, in an all-stock transaction valued at approximately $1.8 million. To view the full press release, visit http://ibn.fm/i9Q4L

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

• A database of clinically validated historical and outcome data from patient tumors
• An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
• A “smart” patient-derived tumor profiling platform
• An in-house bioinformatics artificial intelligence (AI) platform
• A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
• An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Tuesday's trading session at $1.56, up 6.1224%, on 1,786,394 volume with 4,003 trades. The average volume for the last 3 months is 1,008,216 and the stock's 52-week low/high is $1.25/$8.50.

Recent News

• Predictive Oncology Inc. (NASDAQ: POAI) Completes Acquisition of Quantitative Medicine LLC
• Predictive Oncology Inc. (NASDAQ: POAI) Announces Acquisition of Soluble Therapeutics, BioDtech as it Continues Buildout of Precision Medicine Business
• Predictive Oncology Inc. (NASDAQ: POAI) Secures $2.2M Through Warrant Exercise

Bullfrog Gold Corp. (CSE: BFG) (OTCQB: BFGC) (FSE: 11B)

The QualityStocks Daily Newsletter would like to spotlight Bullfrog Gold Corp. (CSE: BFG) (OTCQB: BFGC) (FSE: 11B).

Bullfrog Gold Corp. (CSE: BFG) (OTCQB: BFGC) (FSE: 11B) today announced that its CEO, David Beling, was featured on The Stock Day Podcast with host Everett Jolly. "We started drilling on May 31st, in spite of Coronavirus, and by June 6th we completed a 25-hole program. Everything is going our way and we're quite pleased with what we've accomplished with this program." To view the full press release, visit http://nnw.fm/KP7va

Bullfrog Gold Corp. (the “Company”) (CSE: BFG) (OTCQB: BFGC) (FSE: 11B) is a Delaware corporation engaged in the acquisition, exploration and development of gold and silver properties in the United States. The Company controls strategic lands with established 43-101 compliant resources in one of the most exciting gold exploration areas in the United States. The Bullfrog Gold Project (“Project”) includes a lease/option on much of the lands where Barrick Bullfrog Inc., a subsidiary of Barrick Gold Corp., produced more than 2.3 million ounces of gold and 2.49 million ounces of silver from 1989 to 1999. The Project is located within the prolific Walker Trend about 125 miles northwest of Las Vegas, Nevada.

Project Highlights

• The Company initially acquired 79 unpatented claims and two patents in mid-2011 and has since staked, leased, optioned, or purchased lands that now total 5,250 acres. Via a 2015 lease/option with Barrick, the Project includes the northern one-third of the Bullfrog deposit where most of the current resources in the Bullfrog mine area occur, along with their interest in the Montgomery-Shoshone deposit which gave the Company 100% control.
• In mid-2017, a NI 43-101-compliant report by independent mining consultancy Tetra Tech Inc. estimated measured and indicated (“M&I”) resources of 624,000 ounces of gold and 1.73 million ounces of silver at average grades of 0.70 g/t and 1.93 g/t, respectively. The expansion plans of these two pits were based on a $1200 gold price, use of heap leach processing, and also included 110,000 ounces of inferred gold resources averaging 1.20 g/t. Barrick used conventional milling to process an average gold grade of 3 g/t.
• The established resources and exploration potential of the Project are strongly supported by a large data base obtained from Barrick, including detailed information on 155 miles of drilling in 1,262 holes in the Bullfrog mine area.

Gold Rush in the Bullfrog Territory

The area around Beatty, Nevada has now attracted AngloGold Ashanti, Kinross Gold, Corvus Gold, Coeur Mining as well as the Company and Waterton. In this regard, Northern Empire Resources Corp’s property located a few miles east of the Project was acquired by Coeur Mining in October 2018 for C$117 million, implying a valuation of C$134/oz of inferred resources. As of today, the Company is trading at a significant discount to the valuation at which Northern Empire was purchased (http://nnw.fm/9NaaN), thereby highlighting the Company’s value proposition for investors.

Bullfrog Gold Corp. is focused on enhancing shareholder returns by concurrently advancing Project development and performing exploration drilling programs on several targets identified by the Company.

Secured Financing for 2020 Operations

Bullfrog Gold Corp. raised C$2 million in January 2020 through a private placement of shares priced at C$0.13/share plus a one-half warrant exercisable within two years at C$0.20 on a full warrant basis. The raise was carried out primarily to fund a drill program that started on May 1 (http://nnw.fm/6nZ0m), and was completed on June 6, 2020. Results from drilling 12,520 feet in 25 holes will be released in the coming weeks. The Company subsequently intends to conduct a preliminary financial analysis and complete further drill programs to advance the Project and add value. The financing was subscribed by several influential shareholders, including a former director of Northern Empire, who handled the sale of the company to Coeur Mining, and Eros Resources, the management of which has been involved with several high-profile mining projects and sales in the past.

Gold Prices estimated to average $1,800/oz in 2021

Gold prices have been on a remarkable run in 2020, rising by $245/oz to $1,760 prior to peaking in early May. Global central banks carried out 144 interest rate cuts thus far in 2020, reducing their rates by a cumulative 5,035 basis points (http://nnw.fm/jzZt0). Meanwhile, the IMF has estimated that global governments have introduced fiscal support measures amounting to over $9 trillion since the start of the COVID-19 pandemic (http://nnw.fm/Or9rI). The resulting weakness in the U.S. dollar and eventual inflationary pressures stemming from these measures prompted Credit Suisse to recently hike their gold price forecasts for the full year to $1,701/oz (from $1,570 previously), while the outlook for 2021 has been raised to $1,800/oz (versus $1,600 previously) (http://nnw.fm/Iqg0X).

Management Team

David Beling, CEO, President and Director
David Beling is a Registered Professional Mining Engineer with 55 years of diverse experience in areas such as engineering, development, permitting, construction, financing and management of mines and plants and the building and growth of several corporations. His initial employment included 14 years with Phelps Dodge, Union Oil, Fluor, United Technologies, and Westinghouse, followed by 41 years of senior management and consulting with 25+ U.S. and Canadian mining companies. In 2006-2007, he spearheaded an IPO, successfully drove equity raises totaling C$112 million and grew that Company’s market capitalization to $460 million. Beling has served on 14 boards since 1981, including three mining companies distinguished by the TSX Venture Exchange as top-10 performers.

Alan Lindsay, Chairman of the Board
Alan Lindsay is an entrepreneur and businessman who has founded seven companies within the mining and pharmaceutical industries, including Anatolia Minerals Development Ltd., Uranium Energy Corp., Oroperu Mineral, Strategic American Oil and AZCO Mining. Lindsay also developed the strategic vision for the 2011 acquisition and placement of the Project from NPX Metals into Bullfrog Gold Corp.

Kjeld Thygesen, Director
Kjeld is a graduate of the University of Natal in South Africa and has 48 years of experience as a resource analyst and fund manager. In 1972, he joined James Capel and Co. in London as part of its highly rated gold and mining research team before subsequently becoming manager of N. M. Rothschild & Sons’ commodities and Natural Resources Department in 1979. In 1987, he became an executive director of N. M. Rothschild International Asset Management Ltd., before co-founding Lion Resource Management Ltd., a specialist investment manager in the mining and natural resources sector, in 1989. Thygesen has been a director of Ivanhoe Mines Ltd. since 2001 and served as investment director for Resources Investment Trust PLC from 2002 to 2006.

Tyler Minnick, CFO and Director of Administration & Finance
A registered member of the Colorado Society of Certified Public Accountants with over 24 years of experience within the fields of accounting, auditing, and administrative services. Minnick has been engaged with the Company since mid-2011 and previously worked in the finance department of MDC Holdings/Richmond American Homes, one of the largest residential construction companies in the United States.

Bullfrog Gold Corp. (OTCQB: BFGC), closed Tuesday's trading session at $0.16, up 3.2258%, on 52,400 volume with 16 trades. The average volume for the last 3 months is 146,127 and the stock's 52-week low/high is $0.047449998/$0.209999993.

Recent News

• Bullfrog Gold Corp. (CSE: BFG) (OTCQB: BFGC) (FSE: 11B) CEO Discusses 2020 Drill Program on The Stock Day Podcast
• Bullfrog Gold Corp. (CSE: BFG) (OTCQB: BFGC) (FSE: 11B) Announces Assays on 9 Additional Drill Holes at its Project in Nevada
• Bullfrog Gold Corp. (CSE: BFG) (OTCQB: BFGC) (FSE: 11B) Announces Assay Results on 9 More Holes Drilled at Nevada Project

Kingman Minerals Ltd. (TSXV: KGS)

The QualityStocks Daily Newsletter would like to spotlight Kingman Minerals Ltd. (TSXV: KGS).

Bloomberg pegged 2020 as a “golden year,” noting that “after one of the most geopolitically charged years in recent memory, gold is now set to soar” (http://nnw.fm/fkv8D) — and that was before the market volatility caused by the COVID-19 pandemic. Kingman Minerals (TSX.V: KGS), a Canada-based company engaged in the acquisition, exploration and development of gold and silver properties in North America, looks to be ideally positioned to benefit from the gold boom as investors start “racing back to their favorite safe haven asset.”

Kingman Minerals Ltd. (TSXV: KGS), formerly Astorius Resources Ltd., is engaged in the acquisition, exploration and development of gold and silver properties in North America. The Canada-based company is focused on sourcing and developing high-quality properties in favorable mining locations to advance its diverse portfolio of low-cost, lifelong assets.

The Company maintains the following projects:

The Mohave Project: Located in the Music Mountains in Mohave County, Arizona. Approximately 35 miles from the town of Kingman, the property consists of 20 lode claims, including the historic Rosebud Mine. The Company has entered into an option agreement to earn 100% over four years. According to historic mappings of the mine, probable ore is 15,560 tons. Possible (inferred) ore is comprised of 176,000 tons, and additional possible (inferred) ore totals slightly over 1,100,000 tons. The total contained gold ounces for all categories is estimated at 664,000 ounces, and contained silver is estimated at 2,600,000 ounces. The Company has recently completed two underground reconnaissance and sampling programs and is in the process of verifying previous resource estimates.

 

The Cadillac East Property: Located approximately 55 kilometers east of Val d’Or, a hub for exploration and mining activities in the Canadian province of Quebec. The Company acquired a 100% interest in the property from an arm’s length vendor. Cadillac East Property consists of 12 claims, and the Company has an option agreement to earn 100% over three years. Having been the subject of numerous geophysical and geological surveys, the Cadillac East Property has been explored and surveyed by numerous companies as well as by the Quebec government. Exploration work done in 2017 by Exploration Facilitation Unlimited Inc. revealed multiple potential targets for future investigation, as results from the soil program identified value in gold, silver, copper, zinc and nickel.

Kingman Minerals is focused on enhancing shareholder value as it continues exploring potential assets and acquiring strategic gold targets. The company recently commissioned mining consulting services company Burgex Mining Consultants Inc. to complete two underground gold exploration programs in the historic Rosebud Mine. Burgex specializes in mineral exploration, mining claim staking, landman services, mining consulting, and the access and documentation of abandoned mine sites throughout the western United States and the world. Burgex’s founders have been active in the industry since 2007 and have identified, secured and consulted on hundreds of thousands of acres of mineral properties spanning a wide range of mineral commodities with billions of dollars’ worth of resources and reserves. The Burgex team has been featured in Forbes Magazine as well as on the Discovery Channel and other outlets. Burgex is at the vanguard of industry advancements in safely accessing difficult vertical abandoned mine workings and continues to pioneer new mineral exploration methods with strategic partners throughout the United States and the world.

Gold’s Predicted Rise

The value of gold is currently on an upward climb due to COVID-19’s upending of the global economy, causing governments to expand their balance sheets. In 2019, as a result of the housing and financial crisis, gold saw its best performance since 2010 — increasing as much as 20% and hitting a top price of $1,549 per ounce in September of that year. Analysts predict its price will continue to climb due to strong buying by central banks, a weakening of the U.S. dollar, and increasing political tensions. A recent Wolfe Research report predicted gold would hit an all-time high, referencing an ounce of gold that commanded a $1,515 asking price. As the value of the U.S. dollar weakens, the demand for gold is inversely rising. Known as a safe-haven asset, gold tends to see increased levels of demand during times of consumer fear or recession.

Management

Sandy MacDougall – Chairman and Director
An economics graduate from the University of British Columbia, Sandy MacDougall brings 30+ years of experience in the investment banking and finance industry to KGS. He was instrumental in the acquisition, development and production of gold at the Alto el Toro mine near Ibaguel, Columbia. As a former investment advisor at Canaccord Capital Corp., MacDougall was a key player in multiple significant financings in Canada as well as abroad, working with a wide range of companies. His experience has afforded him critical exposure to precious and base metal projects throughout North and South America, and he has served as chairman of the board since 2016.

Arthur Brown – President and Director
With 36 years of business experience and service to the boards of eight other companies in sectors ranging from technology to oil, gas and mineral exploration, Arthur Brown adds substantial knowledge in corporate structure and development as well as financings and venture capital to the KGS team.

Cyrus Driver – Independent Director
Cyrus Driver was a founding partner in the firm of Driver Anderson from its inception in 1982 and is a chartered accountant as well as a retired partner in the firm of Davidson and Company LLP. Aside from providing general public accounting services to a diverse range of clients, his specialty is servicing TSX Venture-listed companies and members of the brokerage community. With expert knowledge of the securities industry and its regulations, Driver lends valuable advice to his clients regarding finance, taxation and other accounting-related matters. He currently serves as director and chief financial officer of several TSX-V-listed companies.

Dr. Peter Born – Director and Technical Specialist
A professional geologist registered with the Association of Professional Geoscientists of Ontario and a fellow of the Geological Association of Canada, Dr. Peter Born brings 30+ years of experience in exploration and mining to the company. With prior roles as a senior geologist with Western Mining Corporation, he is currently working with RPS Energy Canada Ltd. on natural gas plays related to high-temperature dolomites and sedimentary zinc deposits (MVT) within the Appalachian Basin in the United States. Dr. Born holds a Ph.D. in earth sciences and has expertise in Precambrian sedimentary geology, basin analysis, sedimentology, stratigraphy and sedimentary ore deposits.

Kingman Minerals Ltd. (TSXV: KGS), closed Tuesday's trading session at $0.085, up 13.33%, on 161,500 volume with 11 trades. The average volume for the last 3 months is 90,988 and the stock's 52-week low/high is $0.07/$0.22.

Recent News

• Kingman Minerals Ltd. (TSX.V: KGS) in Prime Position as Investors Return to 'Favorite Safe Haven Asset'
• Kingman Minerals Ltd. (TSX.V: KGS) Positioned to Profit as Rising Gold Prices Renew Investor Interest in Mining Companies
• Kingman Minerals Ltd. (TSX.V: KGS) Set to Benefit as Gold Prices Rally

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its First Quarter 2020 financial results and to provide a business update, including discussions on progress made in the development of the Company's proprietary Ultra Shear Technology™ ("UST™) Platform and in the pending merger of PBI, Cannaworx, and SkinScience Labs.

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed Tuesday's trading session at $2.00, off by 4.7619%, on 26,822 volume with 60 trades. The average volume for the last 3 months is 18,288 and the stock's 52-week low/high is $0.600600004/$4.48999977.

Recent News

• Pressure BioSciences First Quarter 2020 Financial and Business Update to Include Jim Morrison, In-Coming CEO for Merged Companies of Availa Bio
• Pressure BioSciences, Inc. (PBIO) and Leica Microsystems Collaborate to Offer Innovative Combined Workflow Expected to Accelerate Cancer R&D
• Pressure BioSciences Inc. (PBIO) Pending Acquisition Target Secures $3.5M Initial Hand Sanitizer Order

Sugarmade, Inc. (SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (SGMD).

Sugarmade (OTCQB: SGMD), a leading, multidivisional/multiproduct supply company crossing various industries, is focused on developing a diversified brand portfolio and revenue growth through strategic acquisitions. SGMD’s most recent acquisition, BudCars Cannabis Delivery Service has been a particularly strong move for the company as it strengthens its position in the growing hemp market.

Sugarmade, Inc. (SGMD) is headquartered in Monrovia, California, where the company recognizes new opportunities in the cannabis delivery space and in the market for supplies to the quick-service restaurant industry – both of which have fast-changing dynamics due to the recent outbreak of coronavirus in the United States.

The Coronavirus Cannabis Boom Market

Retailers across the nation are closing their doors and curtailing operations due to the coronavirus pandemic, inherently pinching sales. In the California cannabis sector, however, business has never been better – especially relative to home delivery.

California’s cannabis industry continues to operate, and media reports reveal booming cannabis sales as the state’s citizens stay home to wait out current events. The Los Angeles Times recently published the headline, “Marijuana Sales on Fire amid Virus Outbreak; New York Post “Cannabis sales hit new highs”; USA Today “American Stock Up on Pot” Fox News “California marijuana sales surge”; and ABC News Cannabis Shops thrive in coronavirus pandemic.

The state of California benefits from the ultra-high taxes paid by the highly regulated cannabis industry, and has thus deemed cannabis companies as “essential” businesses, allowing for full operations to continue. While pot shops are seeing strong foot traffic, the real growth action is in-home delivery as consumers seek to embrace social distancing. Many delivery operators are reporting difficulty in meeting demand with sales growth of up to 10% sequentially each week. It is certainly a boom time for the industry.

Sugarmade Growth Strategy

Recognizing new investment and operational opportunities within California’s cannabis market, Sugarmade is strategizing to take advantage of opportunity specifically in delivery services (non-storefront retailer), manufacturing via co-branding, and selective genetic cultivation. The company is taking a highly selective approach, targeting only the best of these opportunities for company growth.

In line with this strategy is northern California delivery service Budcars, in which Sugarmade owns a 40% interest and an option to gain a controlling interest. Budcars connects consumers with premium products sourced from top-tier farms and extractors, offering a curated menu of fully compliant cannabis products. The company maintains a competitive advantage by sourcing premium cannabis offerings and same-day delivery. In addition to maintaining its own cars, California licenses, and fulfillment center, Budcar orders its premium products in bulk at lower prices, enabling the company to rein in costs and maintain competitive pricing for its customers. Currently serving major communities within the metropolitan area of Sacramento, Budcars plans to continue the expansion of the company’s delivery reach.

Sugarmade plans to continue its expansion into burgeoning new sectors of the cannabis market through the following avenues:

• Geographic expansion of Budcars delivery scope
• New delivery geographies
• Cannabis cultivation as a key component of a hybrid vertical integration strategy
• Product technology expansion—including products containing exotic and lesser-known cannabinoids

 

Diversified Portfolio

Sugarmade has positive market exposure to cannabis delivery, as well as to the restaurant industry, at a time when these businesses are being force to move toward take-out and delivery models in order to survive.

The company has various business operations in diverse marketplaces, including food, safe packaging and sanitary supplies for various industries, and agricultural supplies. Sugarmade entered the industrial hemp and CBD space by investing in Hempistry, Inc., a privately held Nevada corporation. Hempistry began planting an ultra-high cannabidiol (CBD) industrial hemp strain on a land option it holds on 5,000 acres of prime Kentucky farmland. The strain of industrial hemp being grown by Hempistry is ultra-rich in CBD but contains less than 0.3% of THC, the psychoactive ingredient found in cannabis.

CarryOutSupplies.com, the leader in paper and plastic take-out supplies, serves nationwide customers by offering a wide array of high-quality products that are cost-efficient, custom-made and delivered on time. This business unit currently serves 2,000 quick service restaurants, garnering from 30%-40% of the market share. Sugarmade plans to expand operations via the addition of market share and the introduction of new product offerings.

Market Opportunity

There is little doubt among industry participants, and recently confirmed by Forbes, that California is the single largest cannabis market in the world. The state is expected to produce more than $3.5 billion in cannabis sales during 2020, with growth topping 23% annually. The global industrial hemp market size was estimated at $4.71 billion in 2019 and is expected to register a revenue-based CAGR of 15.8% over the forecast period of 2016-2027, according to Grandview Research. Market growth drivers include the 2018 Farm Bill and society’s increasing knowledge of the benefits of hemp products.

Overall industry growth is great, but specific vertical sector growth is even better. Cannabis delivery is clearly the fastest growing sector of the marketplace and with coronavirus fears the already robust growth rate has accelerated.

Sugarmade seems to be in the right industry at the right time in history.

Management

CEO Jimmy Chan is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, and international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick-service restaurant industry, which merged with Sugarmade in 2014.

Dedicated to getting the highest caliber of THC and CBD to its customers’ door, the company’s priority is to ensure that they receive the highest quality cannabis product free from logistical hassles. Sugarmade specializes in growing and acquiring innovative brands to maximize value for company employees, shareholders and other stakeholders. Sugarmade believes its future is very bright as the company expands operations within the cultivation sector and rapidly increases its revenue base.

Sugarmade, Inc. (SGMD), closed Tuesday's trading session at $0.0039, off by 2.50%, on 72,149,821 volume with 1,506 trades. The average volume for the last 3 months is 52,394,818 and the stock's 52-week low/high is $0.001599999/$0.028.

Recent News

• Sugarmade Inc. (SGMD) Capitalizing on Steep Increase in Cannabis Space, Strengthening Diverse Portfolio
• 420 with CNW - Congress Passes Bill Granting Researchers Access to Commercially Available Marijuana
• 420 with CNW - Colorado Governor Signs Bill Allowing Expedited Pardons for Marijuana Possession Convicts

Round Meadow Holdings Corp.

The QualityStocks Daily Newsletter would like to spotlight Round Meadow Holdings Corp..

Round Meadow Holdings’ (“RMH”) Budtender Awards today named Brandon Scott as 2019 Mastermind Winner. The update reads, “Our 2019 Mastermind winner was Brandon Scott of Mission dispensary in Chicago… He is know-it-all, in the most likable and essential way possible. He is an expert with next-level knowledge and expertise in all aspects of the cannabis industry from strains to terpenes to vapes to edibles & dosing etc!’”

Round Meadow Holdings Corp. is a professional organization that represents accountability, delivering business solutions created exclusively for the expanding cannabis industry. A synergistic portfolio of cannabis service companies, RMH is dedicated to supporting the competitive cannabis landscape and its participants as the industry evolves and faces historic growth spurts and challenges.

Historically, when industries such as cannabis experienced growth spurts, many people rushed to find their position within that space. As the competitive landscape increased, so did the velocity of product offerings. For instance, during the Gold Rush of 1849, most successes were found among companies that provided services to the miners rather than with the miners themselves. Levi Strauss and a few well-known hotel chains and banks know all too well the outcome of offering goods and services to an exploding industry.

RMH recognizes numerous opportunities within the current marketplace and has defined its strategy for success in the evolving cannabis industry. At the core of this strategy is a portfolio of synergistic brands, including Canna Paid, Budtender Awards, BudtenderSelect.com, and High Lifestyle. These separate verticals are designed to provide relevant and much-needed services to the cannabis industry. They are interconnected and supportive of each other, strengthening their positions as a whole.

RMH Companies

Canna Paid
Canna Paid is a merchant services platform that utilizes a unique and proprietary compliance technology to provide cannabis merchants a competitive and standard retail banking solution. Canna Paid works with all major credit card brands, and enables users to send and receive electronic payments.

One of the distinct features of the Canna Paid technology, which significantly benefits the user experience, is that it supports and maintains existing consumer behaviors. The process performs in the same manner as a traditional retail credit card transaction, but incorporates tokenization -similar to how Apple Pay works – to secure the transaction at the highest level. This process protects the merchant and cardholder from fraud and unintentional disputes (“chargebacks”). Furthermore, it simply makes it easy for cannabis dispensaries and customers to seamlessly conduct business. As the Canna Paid portfolio continues to expand, so does the brand equity that secures its position as an industry leader.

FAQ: What happens if cannabis becomes legal nationwide, or what if banking becomes more available for cannabis-related businesses? How will this affect Canna Paid?

As an emerging branded technology and industry leader, Canna Paid remains scalable and closely connected to the growth of the industry and the governing regulations.

Further driving Canna Paid’s appeal as the end-to-end solution for a variety of traditional banks and financial institutions is its capability of providing electronic payment solutions that can integrate with POS systems and simultaneously collect transactional data at the point of purchase. If cannabis becomes legal in all 50 U.S. states (de-scheduled), or if traditional banking becomes more available to business owners in this space, the most valuable factor to conventional banking partners will be the contracts and relationships that Canna Paid has secured. The unique advantages that Canna Paid can offer to a traditional banking partner makes it a prime target for a strategic partnership.

Budtender Awards
RMH excited the cannabis community in 2019 with the creation of the “Budtender Awards,” becoming the first-ever cannabis-related expo and education event at an MGM property and the first at any casino on the Las Vegas strip.

The modern-day “Budtender” is an individual who is helping to redefine and elevate what it means to be someone who works in a dispensary or store where medical or recreational cannabis is sold. Increasingly, this subculture is evolving into a group of highly educated professionals who are continually developing their unique blend of style, food, entertainment, music, fashion, and, most importantly, their recommendations to an ever-growing variety of cannabis offerings. They are educators, advisors, sales professionals, occasionally a “therapist,” and often a trusted resource or friend to their customers.

No matter the role, they are the frontline of the cannabis industry who stand between the thousands of emerging brands, and their would-be customers. Amid this developing group are rising stars who are making a significant impact on the cannabis culture itself.

The 2020 Budtender Awards Experience will take place Sept. 17-19 in Las Vegas at Mandalay Bay Resort and Casino with a full slate of brand activations, pop-up giveaways, vendors, product samples, brand certifications, industry speakers, educational panels, and a Budtender Bootcamp. Networking opportunities, along with a poolside concert series and exclusive VIP parties, add to the unique and exciting atmosphere for expo participants.

Clover Leaf University (“CLU”), the first accredited university specializing in phytotechnology to be approved, regulated, and licensed by the Colorado Department of Higher Education’s Private Occupational School Board, will provide Budtender educational opportunities covering a wide range of topics. CLU delivers the highest quality industry training and the most comprehensive curriculum available today.

Projects in Development

• BudtenderSelect.com – a unique CBD website that will host a variety of Budtender rated CBD products. Visitors will have the option to choose from a variety of products suited to their specific needs. Consumers will be provided with independent reviews of their preferred products, along with suggested ways for use. The Budtender Select shopping cart feature will provide consumers with a convenient and straightforward purchase method.
• HighLifestyle.com – set to be a digital newsletter to cross between RMH brands, specifically with the Canna Paid and Budtender Awards platforms. HighLifestyle.com will be a destination where people can populate, design, and share lifestyle-related content. The nature of this platform is to provide a robust social connection along with the ability to aggregate this collected data for market intelligence.

Leadership

Keith Allen, Chief Executive Officer, Managing Director
Keith Allen has vast executive and operational experience. Allen was formerly the marketing communications expert for ivyKoin, a blockchain-based cryptocurrency for business transactions required extensive verification in the international monetary system, where he helped design the infrastructure and go to market strategy. His other executive experience includes the title of chairman and CEO of a global dental company with products in thousands of retail stores throughout the world. His combined experience with both financial and CPG markets uniquely qualifies Allen to execute and scale the operational goals of Canna Paid and RMH.

Ryan Bridges, Banking & Business Development Officer, Director
Ryan Bridges has extensive investment banking experience with Direct Capital Securities and the California Capital Access Fund, including over 15 years of electronic payment and business development services. Bridges’ extensive operational and developmental expertise was instrumental in generating landmark successes for Radius Payments, Inc. and Payment Insights, LLC. Canna Paid and RMH are the direct benefactors of Bridges’ input and strategic guidance.

* In the first round of financing, Round Meadow Holdings has raised 3mm to date and is currently in phase two raising an additional 2mm for expansions purposes.

Recent News

• Round Meadow Holdings Corp.’s Budtender Awards Recognizes Brandon Scott
• Round Meadow Holdings Corp.’s Budtender Awards Recognizes Lydell Francisco
• Round Meadow Holdings Corp.’s Budtender Awards Recognizes Ashley Cardenas

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF)

The QualityStocks Daily Newsletter would like to spotlight Green Growth Brands Inc. (OTCQB: GGBXF).

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) was featured today in the 420 with CNW by CannabisNewsWire. Although plenty of states have now legalized medical and recreational marijuana in various forms, it still carries a lot of stigma. Most employers are uncomfortable with employees consuming cannabis, even during non-work hours, and plenty of sports organizations do not allow their athletes to use marijuana. The military has a harsh stance on marijuana too, and veterans who admit to using marijuana even in a legal state can be barred from reenlisting.

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) is a lifestyle-oriented cannabis and cannabidiol (“CBD”) consumer products company with a portfolio of lifestyle brands customized to connect specific, like-minded customers. Each Green Growth Brand provides the best quality products within a retail experience that appeals to users in an environment that is emotionally branded and easy to navigate.

In the next five years, the cannabis industry will generate more than $28 billion of new revenue from an estimated 14 million new customers, according to Ackrell Capital’s 2018 Cannabis Investment Report. Meanwhile, Hemp Business Journal projects that the CBD market will increase 8x to $3 billion by 2021, up from $200 million in 2017. Green Growth Brand intends to dominate in these markets with a lineup up products grown, manufactured and presented with the highest quality standards in mind.

Products under the Green Growth Brand umbrella include:

• CAMP: A kiosk-type store where consumers can experience beautifully crafted lifestyle products that enhance one’s journey to self-discovery.
• Seventh Sense: A CBD-infused body care collection crafted from the finest botanicals and fragrances on earth. Created to maximize the properties and aromatics of each ingredient, Seventh Sense natural products are CBD-infused botanical therapy.
• Meri+Jayne: Fiercely authentic and wholly unapologetic, Meri+Jayne is a youthful, full-on celebration of what makes each person unique. Expect the unexpected when it comes to this mix of amazing products.
• Green Lily: A place for women to explore a new world of wellness. With advice on every product, from efficacy to usage, Green Lily guides guests through beautiful new ways to experience cannabis and CBD.
• The +Source: Located in Las Vegas and Henderson, Nevada, The+Source dispensaries operated by Green Growth Brands serve both medical patients and retail customers. Green Growth Brands also operates a grow and production facility in Post, Nevada, and recently entered into definitive agreements to acquire a Pahrump, Nevada, cultivation facility.
• XanthicBiopharms is the owner of valuable intellectual property that turns THC(Tetrahydrocannabinol) and CBD into a water-soluble substance. As a result of combining Green Growth Brands and Xanthic, this technology is being used to create incredible new products.

Business Strategy

Green Growth Brands has identified numeroushitches in the current cannabis retail space. The company intends to counter these challenges and provide a customer experience ripe with a friendly staff, in-stock assortments, efficient operations and more. The company’s retail partners provide distribution opportunities within 4,000 stores, as well as robust and established digital platforms to best reach the modern consumer.

Management

Green Growth Brands brings together a collection of expert retailers, scientists, botanists, developers, artists and business leaders for the benefit of building community. Led by an executive management team steeped in decades of experience with several of America’s most successful brands, including Victoria’s Secret, American Eagle Outfitters, Bath & Body Works, Limited Brands and Designer Shoe Warehouse, Green Growth Brands is uniquely positioned to create memorable brands, retail experiences, and quality products for the emerging cannabis industry.

Chief Executive Officer Peter Horvath heads strategy and execution across all company channels, and previously took shoe retailer DSW public on the NYSE at $1.5 billion. As a dynamic, creative brand leader, team builder, and specialty retail veteran with deep roots in finance, Horvath’s unique ability to understand the big picture while never missing the subtle details is a critical factor in Green Growth Brands’ success and brand popularity among customers.

Chief Marketing Officer Scott Razek is a brand strategist, storyteller and strategic marketer. Razek‘s 25 years of experience in brand building, product development and customer experience focus are a key differentiator for the Green Growth Brands portfolio.

CAO Ed Kistner brings 33 years of multifaceted experience at leading retail businesses, notably in finance, merchandise planning, operations and stores. His well-rounded experiences in fast-changing environments position Kistner to be the architect of the operational execution at Green Growth Brands.

CSO Kellie Wurtzman brings significant retail leadership to Green Growth Brands with a proven track record of leading high-performance stores and teams across multiple retail sectors. Her unmatched experience in identifying and supporting developing business opportunities is ideal for evolving the cannabis industry and will be instrumental in expanding operations at Green Growth Brands.

Headquartered in Columbus, Ohio, Green Growth Brands is traded on the Canadian Securities Exchange and on the OTCQB, providing investors with increased access to data, transparency and liquidity.

Green Growth Brands Inc. (OTCQB: GGBXF), closed Tuesday's trading session at $0.0179, up 11.875%, on 337,297 volume with 48 trades. The average volume for the last 3 months is 1,136,754 and the stock's 52-week low/high is $0.0092/$2.63499999.

Recent News

• 420 with CNW - Congressional Committee Approves Measure Allowing Marijuana Users to Reenlist in the Military
• 420 with CNW – Survey Shows That Canadians Aren’t Moved by Cannabis Branding
• Green Growth Brands (CSE: GGB) (OTCQB: GGBXF) 420 with CNW - Why NJ Medical Cannabis is Slated to Get a Lot Cheaper

iClick Interactive Asia Group Ltd. (NASDAQ: ICLK)

The QualityStocks Daily Newsletter would like to spotlight iClick Interactive Asia Group Ltd. (NASDAQ: ICLK).

iClick Interactive Asia Group (NASDAQ: ICLK), an independent online marketing and enterprise data solutions provider in China, today announced that it was named "Asia Pacific's Leader in Smart Marketing Solutions" at the Mediazone Group's "Asia's Most Valuable Service Providers Awards 2020." The Company also garnered Certificates of Merit for "Excellence in Marketing Technologies, China-Market Solutions and Project Management and Customer Services." To view the full press release, visit http://nnw.fm/vR4is

iClick Interactive Asia Group Ltd. (NASDAQ: ICLK) is an independent online marketing and enterprise data solutions provider connecting worldwide marketers with audiences in China. Built on cutting-edge technologies, iClick’s proprietary platform possesses omni-channel marketing capabilities and fulfills various marketing objectives in a data-driven and automated manner, helping international and domestic marketers reach their target audiences. Headquartered in Hong Kong, iClick operates in 10 locations worldwide, including Asia and Europe.

iClick aims to become a fully integrated Enterprise and Marketing Cloud Platform in China, providing clients a full consumer-cycle solution. This is facilitated by two pillars’ growth strategy through two business segments: Marketing Solutions and Enterprise Solutions.

Marketing Solutions

Using data and AI-driven technology to help brands efficiently identify, target and acquire the right customers

As the leading programmatic marketing platform in China, iClick’s proprietary platform collects a wealth of data from multiple sources to precisely reach the right audience at the right moment, on the right channel and right device. Cross-screen search solutions capture critical micro-moments when users proactively search for what they need. This multi-dimensional approach to marketing allows iClick to effectively understand internet users and exponentially widen target audiences for its brand clients. Multiple monetization models available in the Marketing Solutions segment allow iClick to serve its clients in several ways, such as audience targeting.

Data-driven marketing is indispensable to marketers targeting specific audiences in China. More than 825 million internet users in China are anonymously profiled on iClick’s platform, which boasts cross-channel and cross-screen capabilities.

Enterprise Solutions

Enabling brands to efficiently manage their consumers through online and offline data integration and analysis, increase the repurchase rate, and enhance consumers’ loyalty

iClick’s Enterprise Solutions segment addresses enterprise needs in China, particularly focusing on “smart retail,” an expanding and innovating market involving the combination of online and offline consumers’ behavioral information. Enterprise Solutions support detailed profiling of customers, which facilitates data-driven business strategies, enhances business processes at various levels, and increases operational and marketing efficiency.

Enterprise Solutions leverages iClick’s proprietary platform that incorporates Artificial Intelligence (AI) to learn, build and store knowledge, enabling accurate predictions about consumer behavior that ultimately provide marketing solutions derived from the large amount of available data.

Through a strategic partnership with Tencent, iClick’s Enterprise Solutions presents strong recurring revenue streams with tremendous opportunities to upsell multi-national corporations (MNCs). Tencent’s proprietary API connection enables brands to build 360-degree consumer profiles based on the collection and integration of purchased behavioral information from online and offline touchpoints, including WeChat Mini Programs, WeChat Payment, WeChat Work and more.

As iClick continues to provide integrated marketing and smart retail solutions targeting Chinese consumers, the company believes Enterprise Solutions has strong long-term growth potential and will become a major gross margin contributor in the future.

Partnerships

In 2019, iClick established various agreements and partnerships with a number of leading southeast and northeast Asian companies for regional diversification and in 2020 is focused on continuing to develop additional partnerships and new business models globally. Many of the world’s top companies are leveraging iClick’s proprietary data platform to precisely identify and reach out to core target audience groups in China.

The company’s partnerships include:

• A tri-partnership with BTG WELINK, an online retail services arm of Beijing Tourism Group (“BTG”), and Tencent Holdings Ltd., China’s leading provider of internet value added services. As part of this partnership, iClick applies its upgraded solutions to build a private DSP (Demand Side Platform) system for BTG. Using Tencent’s big data advertising platform, iClick can assist BTG to develop precision marketing campaigns.
• An Advertising Agency Authorization Certificate from Baidu Inc. (NASDAQ: BIDU), under which iClick is designated the authorized agency for native advertising of Baidu’s news feed ads. Native advertising is a consumer-friendly, non-disruptive advertising format that has gained rapid popularity among advertisers in recent years. Native advertising and creative marketing content have become a more effective marketing method among the Chinese young consumers. In 2019, the native advertising sector was estimated to have an around 53.5% share of the online advertising revenue, according to Statista.
• A joint-venture partnership with VGI Global Media Plc (VGI.BKK), Thailand’s No. 1 online to offline (O2O) solutions provider across advertising, payment and logistics platforms, which enables brands in Southeast Asia to capture the multi-billion-dollar Chinese consumer market through a range of technology-driven marketing solutions.

Case Study: Armani Hotel Dubai

Dubai has been gearing up to welcome the growing wave of Chinese visitors. Chinese nationals are eligible for a 30-day visa-on-arrival into the UAE, which gives Chinese travelers tremendous convenience. In light of this, Armani Hotel Dubai set the objective to increase its sales in this market.

The challenge: What Aarmani Hotel Dubai lacked in executing this goal was insightful understanding of Chinese travelers in particular the demographics that were likely to be attracted to the hotel. Challenged by the huge differences in the business practice, unique culture and language barrier in running digital campaigns in China, Armani Hotel Dubai turned to iClick’s know-how and expertise to guide its campaign to success and meet its sales goal.

The solution: iClick tailored an optimal solution for the hotel to increase brand awareness and booking rate from China – which is the key market for the hotel – and successfully assisted Armani Hotel Dubai in reaching its target Chinese audiences by using China’s most popular mobile and internet sites, including WeChat and Weibo, to improve reach and booking potential.

The results: Due to iClick’s unrivaled technological and execution strengths, Armani Hotel Dubai’s ads were delivered in an omnichannel manner, raising brand awareness and garnering interest between Chinese consumers. Subsequently, Armani Hotel Dubai saw a surge in conversion rate.
During the campaign, the Armani Hotel Dubai brand was connected with 87% of Chinese mobile users.

Award-winning Provider

iClick, a Deloitte Technology Fast50, has received multiple industry awards from the international marketing community. The company is committed to helping clients access digital China with its omni-channel, data-driven marketing solutions that deliver uniquely sharpened marketing capabilities and outstanding advertising results.

Most recently, iClick subsidiary OptAim (Beijing) Information Technology Co., Ltd was recognized by Tencent Ads as a 2019 Gold Service Provider. Tencent Ads also named OptAim the winner of three major annual awards for the second half of 2019: “Outstanding Contribution of the Year,” “Best Technology & Data Application Award,” and “Best Branding Awards.”

In November 2019, company co-founder and CEO Sammy Hsieh was chosen as the winner of the “EY Entrepreneur of The Year China 2019 Award in Technology Category,” an award recognizing his entrepreneurial acumen, innovative spirit and strong leadership. As one of the world’s most prestigious business accolades, the “EY Entrepreneur of The Year” awards program honors those who accomplish success by combining ability with opportunity, and inspire others with great vision, leadership and outstanding achievement.

iClick won the Annual Influential Platform Award and the Innovation Golden Award in Marketing at the Creative Award 2019, as well as the Best Tourism Marketing Agency. The company was also the recipient of the “Best Brand and Performance Marketing Award” at the Performance Marketing Ecosystem Summit 2018 hosted by the Advertising & Marketing Service, a division of Tencent Holdings Limited.

The company in 2018 was also recognized as “Platinum Service Partner of Tencent Social Ads” at the Tencent Key Accounts Mid-Year Summit held in Beijing. The mobile division of iClick, Optaim, received the same award beginning in 2016. Optaim was also the “Best DSP Partner” and “Key Account Data Partner” of Tencent, making it the only player in China with such unique and deep level of cooperation with Tencent Social Ads.

Leadership

Sammy Wing Hong Hsieh, chairman of the board and co-founder, was CEO from 2009 to 2019. Prior to co-founding iClick, Hsieh held senior positions in several prominent technology companies. He was general manager for Asia Pacific at Efficient Frontier (now an Adobe company), a leading digital performance marketing company, and was director of Search Marketing at Yahoo Hong Kong from 2000-2008. Hsieh received a bachelor’s degree in economics from the University of California, Los Angeles.

Jian Tang, director, CEO and co-founder, has 20 years of experience in digital advertising and is well-known in China for his expertise in advertising technologies and big data. In 2012, he founded OptAim, which was acquired by iClick in 2015, and has served key research, engineering and management roles at Yahoo’s global research and development center. Tang received his doctorate in computer engineering from Tsinghua University and was named by Campaign Asia as one of the leaders in its Digital A-List in 2016.

Terence Chi Wai Li, chief financial officer, has 15 years of experience in financial management, investment and business operations. He has served in management roles and advisory capacities at several start-ups, in addition to financial management and fundraising roles. He previously worked at PricewaterhouseCoopers, specializing in M&A due diligence and cross border tax and deal structuring projects. Li received an MBA from Oxford University’s Said Business School. He is a Fellow Member of ACCA, a Member of HKICPA, and a Chartered Financial Analyst.

iClick Interactive Asia Group Ltd. (NASDAQ: ICLK), closed Tuesday's trading session at $5.33, off by 1.6605%, on 352,444 volume with 1,923 trades. The average volume for the last 3 months is 488,761 and the stock's 52-week low/high is $2.73000001/$5.98999977.

Recent News

• iClick Interactive Asia Group Limited (NASDAQ: ICLK) Recognized as "Asia Pacific's Leader in Smart Marketing Solutions" by Mediazone Group
• iClick Interactive Asia Group Limited (NASDAQ: ICLK) Recognized for Big Data in Advertising at SBR's Technology Excellence Awards 2020
• iClick Interactive Asia Group Limited (NASDAQ: ICLK) Announces $22M Private Placement

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Genprex Inc. (NASDAQ: GNPX) was featured today in a publication from BioMedWire, examining how a University of Oxford spinout focusing on genomics will benefit from a seed round of $11.4 billion. It aims at improving cancer detection by measuring epigenetic changes to tumor DNA circulating in a patient’s blood. The oversubscribed seed funding round was pioneered by Oxford Sciences Innovation. It is a local early-stage investment enterprise connected to the University of Oxford.

Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed Tuesday's trading session at $3.13, off by 0.634921%, on 870,668 volume with 2,517 trades. The average volume for the last 3 months is 2,714,767 and the stock's 52-week low/high is $0.231000006/$7.0300002.

Recent News

• UK Company Secures Funds to Detect Epigenetic Cancer Signs
• Genprex, Inc. (NASDAQ: GNPX) Joins Russell 3000(R) Index
• Genprex, Inc. (NASDAQ: GNPX) USAN Approval Marks Another Step in Advancement of Lead Drug Candidate for NSCLC

Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF)

The QualityStocks Daily Newsletter would like to spotlight Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF).

Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF) is among the companies presenting at the upcoming Cannabis & CBD Industry Virtual Investor Conference. Virtual Investor Conferences today announced the agenda for the upcoming Cannabis & CBD Industry Virtual Investor Conference. Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 10:15 AM ET, with the first live webcast at 10:30 AM ET, on Thursday, July 9th. REGISTER AT:  https://tinyurl.com/070920VICPRAgenda

Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF) is a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates. The company’s cannabidiol (“CBD”) yeast-based biosynthesis program produces a high yield, ultrapure, low-cost and scalable manufacturing solution for pharmaceutical, food, beverage and personal care consumers of CBD.

The company is headquartered in Calgary, Alberta, Canada.

Biosynthesis Platform

Willow’s proprietary yeast-based lab strains produce CBD, tetrahydrocannabinol (“THC”), and cannabigerol (“CBG”), as well as certain minor and novel cannabinoids.

The company’s expertise in the esoteric field of biosynthesis and in delivering commercial fermentation pathways for the production of pharmaceutical-grade compounds grew from its origins in opiate research. Willow recently delivered a de novo biosynthesis pathway in yeast for thebaine, a key precursor API used as a feedstock in the manufacture of semi-synthetic opiates such as naloxone (used to reverse opioid overdose) and several common analgesics. Led by Chief Scientific Officer Dr. Peter Facchini, Willow’s research team discovered and patented numerous previously unknown genes coding for core catalytic pathway enzymes, as well as a number of additional non-pathway, yet commercially-essential, accessory genes.

Utilizing this proven synthetic biology platform, Willow’s research team has already begun producing cannabinoids at lab scale, using yeast as the host cell “factory.” This biosynthetic fermentation-based process is capable of producing pharmaceutical grade CBD in 10 days – far less time than traditional plant-based extraction methods.

Willow anticipates its technology can be scaled to produce hundreds of kilograms per batch of cannabinoid API at less than $1,000 per kilogram, thus costing approximately 60% less than current chemical synthesis methods and 90% less than conventional plant-based extraction methods.

World-Class Collaboration

Willow and Noramco Inc., the world’s largest producer of high-quality synthetic cannabinoid APIs and other controlled substance APIs for the pharmaceutical and healthcare industry, have an exclusive, worldwide Joint Development Agreement (“JDA”) to design a yeast-based biosynthesis platform for the production and distribution of a highly pure CBD isolate.

The mutually exclusive agreement calls for Willow to be responsible for optimizing yeast strains in a biosynthetic process to generate ultrapure CBD at high yield and substantially lower cost compared to current methods. Noramco will leverage its decades of experience in producing and delivering CBD and pharmaceutical APIs by being responsible for the scale-up, regulatory submission, marketing and distribution of products manufactured under the JDA.

Each company will invest comparable funds, will retain the intellectual property associated with their respective scopes of work and share equally in gross profits from sales of products manufactured under the JDA.

Market Opportunity

The agreement with Noramco (http://nnw.fm/Mz1vW) addresses the increasing demand for CBD-based APIs and other CBD-infused products by pharmaceutical, nutraceutical, consumer packaged goods, beverages and other industry sectors.

The U.S. market potential of cannabinoids is significant, with industry analysts projecting $50 billion in cannabinoid-based pharmaceutical sales and $16 billion in CBD consumer goods retail sales by 2025. As of June 2019, 34 U.S. states and the District of Columbia, Guam, Puerto Rico and U.S. Virgin Islands have legalized cannabis for medical use. Another 13 states and territories have approved recreational cannabis for adult use while other states are considering similar measures.

The cannabinoid API market continues to evolve with CBD and other cannabinoid-based treatment options currently in clinical trials for indications such as post-traumatic stress syndrome, epilepsy, Parkinson’s disease, chronic pain, schizophrenia, cancer treatments and other challenging unmet medical conditions.

Capitalization

Willow is fully funded after raising $29 million via private placement and $8 million in exercised warrants by Tuatara Capital Fund II, L.P. Proceeds of the funding will be used to enhance the existing laboratory space in Calgary and Vancouver, Canada, and in San Francisco, California. The company anticipates exiting 2020 with $15.8 million in cash.

Leadership

President and CEO Trevor Peters is an experienced executive who co-founded four startup companies in the past 15 years. He has raised over $1 billion in equity and debt financings at various stages of corporate development and has been integral to successful transactions totaling over $4 billion on sale. Mr. Peters previously was chief financial officer at Caracal Energy Inc., which sold to Glencore plc in 2014 for $1.8 billion.

Chief Financial Officer Travis Doupe has over 18 years of experience in financial leadership roles, principally in the international oil and gas industry, where he provided corporate strategic direction while overseeing all aspects of financial operations. Mr. Doupe is the treasurer and a member of the board of directors of the Canada Council for the Americas – Alberta and holds a CA-CPA designation and earned a bachelor’s degree in management from the University of Calgary.

Dr. Peter Facchini, Chief Scientific Officer, has been professor of plant biochemistry in the Department of Biological Sciences at the University of Calgary since 1995. He is recognized internationally as a leader in plant specialized metabolite biosynthesis. Dr. Facchini is the Canada Research Chair in Plant Metabolic Processes Biotechnology and has published more than 150 research papers and scholarly articles. Dr. Facchini received a PhD from the University of Toronto and conducted postdoctoral research at the University of Kentucky and Université de Montréal.

Dr. Joseph Tucker, Executive Chairman of the Board of Directors, holds more than 20 issued or pending patents and is a member of the Board of Directors of BioAlberta. He has extensive senior leadership experience in multiple public and private biotech companies. Dr. Tucker received a PhD in biochemistry and molecular biology from the University of Calgary.

Willow Biosciences Inc. (OTCQB: CANSF), closed Tuesday's trading session at $0.38134, off by 0.43342%, on 10,495 volume with 3 trades. The average volume for the last 3 months is 42,359 and the stock's 52-week low/high is $0.218999996/$0.819999992.

Recent News

• Live Investor Conference & Webinar: Cannabis & CBD Biopharma Industry Companies Present July 9th
• Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF) to Present at VirtualInvestorConferences.com
• Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF) Appoints New SVP to Lead Sales and Marketing of New Line of Cannabinoids

Cannabis Global, Inc. (OTC: MCTC)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Global, Inc. (MCTC).

Cannabis Global (OTC: MCTC), a cannabinoid and hemp extract science-forward company developing infusion and delivery technologies, today announced the completion of initial product development of the Hemp You Can Feel(TM) product lines, and the launch of the next phase of the Company's operations, which will focus on bringing the product lines to the marketplace. According to the update, Cannabis Global will be launching several new product marketing initiatives designed to move its innovative hemp extract and rare cannabinoid products into the marketplace over the next coming weeks. To view the full press release, visit http://cnw.fm/tP2mM

Cannabis Global, Inc. (OTC: MCTC) is an innovator in the field of cannabinoid nanoparticles and infusion technologies with several important cannabinoid patents filed and an active research and development program underway. The company was reorganized during June of 2019 and announced its intent to enter the cannabis sector and change its corporate identity to Cannabis Global Inc. The company is headquartered in Los Angeles, California.

With the hemp and cannabis industries rapidly expanding in terms of market size, acceptance and number of market participants, MCTC plans to concentrate its efforts on the middle portions of the hemp and cannabis value chain. The company is actively pursuing R&D programs and productization of advanced cannabinoid delivery systems, based on solid polymeric nanoparticles and fibers. These technologies hold the promise to revolutionize the science of cannabinoid bio-enhancement for use in foods, beverages, consumer products and in transdermal applications. Because of nanoparticles’ ability to be quickly absorbed into the bloodstream, nanotechnology has been utilized in the food and drug industry for some time and has the potential for tremendous growth in the cannabis industry (http://nnw.fm/v6RQ6).

Cutting-Edge Technology

MCTC is at the cutting-edge of the cannabis industry’s trends with its emphasis on polymeric nanotechnology. This is not to be confused with the more basic oil-in-water nano-emulsions currently marketed to the food and beverage industry. The company’s polymer-based particles offer significant loading of active ingredients and unmatched flexibility and customization, allowing for myriad combinations of cannabinoids with unique performance characteristics. MCTC believes polymeric nanotechnology particles will be a critical technology area for the cannabinoid formulation marketplace.

The company continues to build its R&D program, specifically researching the development of improving methods to make cannabinoids available to living systems. Instrumental in the research program is the development of novel polymeric nanoparticles and nanofibers. These have the potential to elevate the potential of cannabinoid products in the following ways (http://nnw.fm/cK3Bl):

• Significantly improving bioavailability
• Allowing for ultra-high loading rates
• Enhancing customization of cannabinoid combinations
• Improved dosing precision
• Providing more control in release parameters

MCTC leadership understands the importance of developing intellectual property (IP) in the ever-evolving cannabis industry. A recent Forbes article described IP as “critical for creating true differentiation between companies and their product and service offerings” (http://nnw.fm/57Fjh). Recognizing the importance of IP, MCTC has been consistent in its application for patents to protect its innovative nanotechnology applications.

Patents

MCTC has now filed four patents on its cannabinoid delivery technology systems:

• The company first collaborated with Cannabis Nanosciences Inc. on technologies. This became the basis for its first patent filing on an innovative edible dissolvable film for cannabinoid ingestion.
• Its second patent filing for cannabinoid nanoparticles combined TPGS, a water-soluble form of vitamin E.
• Its third patent filing involved a unique 4th dimension, 3D printed cannabinoid delivery system for beverages.
• Its fourth patent, considered its most significant, broadly covers many aspects of nanoparticles and nano fibers comprising one or more cannabinoids disposed at least partially within a water-soluble medium.

Collaborations

MCTC collaborated with Marijuana Company Inc. (OTCQB: MCOA) subsidiary hempSmart Inc., under a hemp extract and CBD product supply agreement wherein hempSmart will utilize its extensive network of marketing partners to market MCTC’s powered drink mixes and other CBD edibles online. These products are designed for the dry beverage and edibles sector and will be supplied by MCTC. They incorporate the company’s patent-pending cannabinoid infusion technologies and will be trademarked as Hemp You Can Feel (TM) and Gummies You Can Feel (TM).

Leadership

MCTC CEO and chairman Arman Tabatabaei boasts 15 years of management and operations experience and is considered an expert at data collection and analysis relative to resource management, risk forecasting, and profit and loss management. He has acted as a consultant with Cannabis Strategic Ventures (OTCQB: NUGS) and played an instrumental role in improving operations at Sugarmade Inc. (OTCQB: SGMD) relative to the company’s hydroponic growth supplies initiatives.

MCTC founder and director Robert Hymers also brings a seasoned perspective, having had significant experiences in the cannabis industry and as a financial executive and consultant. He is the managing partner of Pinnacle Tax Services in Los Angeles and was previously CFO and director of Marijuana Company of America Inc. (OTC: MCOA). He is currently a member of the Strategic Advisory Board at Massroots Inc. and acts as a consultant to both Cannabis Strategic Ventures Inc. and Sugarmade Inc. Hymers’ background in tax accounting, auditing, SEC reporting, mergers and acquisitions, and corporate finance has immense value in his current position at MCTC Holdings.

Cannabis Global, Inc. (MCTC), closed Tuesday's trading session at $0.23145, off by 4.3595%, on 24,904 volume with 20 trades. The average volume for the last 3 months is 65,237 and the stock's 52-week low/high is $0.05/$3.00.

Recent News

• Cannabis Global, Inc. (MCTC) Announces Launch of Marketing Phase for Hemp You Can Feel(TM)
• Cannabis Global, Inc. (MCTC) Launches Newest Line of Branded Products - "Hemp & Booch" Super Premium Kombucha
• U.S. Consumers Project to Spend Nearly $3 Billion On Cannabis-Infused Products In 2020